Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/31895
Title: Chronic hepatitis b prognostic markers other than pre-treatment viral load predicted composite treatment outcome
Authors: Myo Nyein Aung
Wattana Leowattana
Khine Nwe Win
Noppadon Tangpukdee
Sant Muangnoicharoen
Juntendo University
Mahidol University
Boromrajonani College of Nursing Nakhon Lampang (BCNLP)
Keywords: Immunology and Microbiology;Medicine
Issue Date: 23-Jul-2013
Citation: Journal of Infection in Developing Countries. Vol.7, No.7 (2013), 541-549
Abstract: Introduction: Chronic hepatitis B (CHB) is a globally common infectious disease. Its clinical course is complicated. In Southeast Asia, nucleos(t)ide analogues (NA) are commonly used drugs for CHB treatment. Composite treatment outcome has often been used in CHB clinical practice, but rarely predicted epidemiologically. This study aimed to compare the composite treatment outcome between CHB patients with low and high treatment-naïve viral load, and to identify its predictors Methodology: This retrospective cohort study followed up 95 CHB patients on NA treatment for a year. Composite treatment outcome was defined as undetectable HBV DNA level, ALT normalization and, HBeAg clearance in the case of HBeAg-positive patients. Multinomial logistic regression analysis was applied to analyze the significant treatment response predictors. Results: Complete composite treatment outcome was achieved by 52% of CHB patients with an initial viral load < 6.5 log 10 copies /ml, but 31% of those had an initial viral load ≥ log 6.5 log 10 copies /ml. Outcome was predicted by HBeAg negativity (adjusted relative risk ratio, aRRR = 11.1, 95 % confidence interval, CI 3-41.3) and ALT normalization within the sixth month of therapy (aRRR = 6.7, CI 1.8-24.9). An elevation of ALT to more than 1.5 times the normal value (40 IU/ml) can lead to an incomplete response on NA therapy (aRRR = 6.2, CI 1.5-26.6.) Conclusion: Routine clinical markers other than pre-treatment viral load predicted composite CHB outcome on NA Therapy. © 2013 Aung et al.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84880295448&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/31895
ISSN: 19722680
20366590
Appears in Collections:Scopus 2011-2015

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.